S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 247 000 KRW -2.56% Market Closed
Market Cap: 5.8T KRW

Sam Chun Dang Pharm Co Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sam Chun Dang Pharm Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Revenue
â‚©215.1B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
6%
Yuhan Corp
KRX:000100
Revenue
â‚©2.2T
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
8%
SK Biopharmaceuticals Co Ltd
KRX:326030
Revenue
â‚©620.3B
CAGR 3-Years
21%
CAGR 5-Years
151%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Revenue
â‚©1.5T
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
6%
C
Caregen Co Ltd
KOSDAQ:214370
Revenue
â‚©81.1B
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
N/A
C
Celltrion Pharm Inc
KOSDAQ:068760
Revenue
â‚©507.5B
CAGR 3-Years
7%
CAGR 5-Years
23%
CAGR 10-Years
22%
No Stocks Found

Sam Chun Dang Pharm Co Ltd
Glance View

Market Cap
5.7T KRW
Industry
Pharmaceuticals

Sam Chun Dang Pharm Co Ltd is a quintessential tale of innovation and resilience in the ever-evolving pharmaceutical landscape. Founded in 1943, this South Korean company has steadily crafted its way into becoming a significant player in the generic drug market. Initially focusing on traditional herbal remedies, the company astutely shifted its focus towards the production of generic drugs, capitalizing on the increasing demand for cost-effective alternatives to branded medications. Sam Chun Dang's business model pivots on manufacturing and distributing a wide range of pharmaceutical products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients, catering to both domestic and international markets. The company thrives by meticulously investing in research and development, ensuring a robust pipeline of new generics ready for market entry as patents on branded drugs expire. By emphasizing quality and affordability, Sam Chun Dang Pharm Co Ltd leverages its state-of-the-art manufacturing facilities, accredited by international standards, to maintain a competitive edge. Their profitability stems from not only their comprehensive product lineup but also strategic partnerships and collaborations that enhance their market penetration. Despite operating within a highly competitive and regulated industry, Sam Chun Dang’s commitment to consistent quality and innovation helps them sustain revenue growth and solidify their position as a reputable pharmaceutical provider.

Intrinsic Value
8 150.14 KRW
Overvaluation 97%
Intrinsic Value
Price
S

See Also

What is Sam Chun Dang Pharm Co Ltd's Revenue?
Revenue
215.1B KRW

Based on the financial report for Jun 30, 2025, Sam Chun Dang Pharm Co Ltd's Revenue amounts to 215.1B KRW.

What is Sam Chun Dang Pharm Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
6%

Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Sam Chun Dang Pharm Co Ltd have been 7% over the past three years , 3% over the past five years , and 6% over the past ten years .

Back to Top